Kuros Biosciences AG
SIX:KURN
Kuros Biosciences AG
SIX:KURN
Price:
7.15 CHF
8.33%
Market Closed
Updated:
May 13, 2024
Section:
Relative Value
The Relative Value of one
KURN
stock under the Base Case scenario is
3.98
CHF.
Compared to the current market price of 7.15 CHF,
Kuros Biosciences AG
is
Overvalued by 44%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
KURN
Relative Value
Base Case
3.98
CHF
Overvaluation 44%
Valuation Multiples
Multiples Across Competitors
KURN Competitors Multiples
Kuros Biosciences AG Competitors
Kuros Biosciences AG Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CH |
|
Kuros Biosciences AG
SIX:KURN
|
262.9m CHF | 7.8 | -19.2 | -42.4 | -28.9 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
283.9B USD | 5.2 | 58.9 | 12.8 | 19.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
166.4B USD | 5.6 | 44.2 | 18.6 | 30.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.9B USD | 11 | 30.1 | 24.2 | 25.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.3B USD | 8.2 | 27.8 | 22.5 | 24.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
134.9B AUD | 6.3 | 36 | 21.8 | 27 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
82.2B USD | 3 | 169.8 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
44.9B USD | 8.7 | -7.5 | -8.1 | -7.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.3B USD | 3.3 | 27.6 | 14.1 | 17.7 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40T KRW | 18.4 | 74.6 | 45.6 | 62.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
